Over Active Bladder Instillation Study - Botox

Urinary Incontinence Clinical Trial

Official title:

Evaluation of the Efficacy of Botulinum-A Toxin/DMSO Instillation in the Treatment of Women With Over Active Bladder (OAB) Syndrome and/or Urinary Urge Incontinence

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00667095
• Other study ID #: 07-007399
• Status: Terminated
• Phase: Phase 3
• First received: April 23, 2008
• Last updated: July 10, 2014
• Start date: April 2008
• Est. completion date: January 2012

Study information

• Verified date: July 2014
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether women with overactive bladder (OAB) who receive direct instillation via a catheter of a Botulinum-A Toxin (Botox) with Dimethyl Sulfoxide (DMSO) solution experience significantly better improvement of their OAB symptoms when compared to a similar group of women with OAB who receive instillation of DMSO only.

Description:

The primary objective of this study is to evaluate the efficacy of catheter-based instillation of a solution of Botox/DMSO as a novel method for treating women with overactive bladder (OAB) and secondary urinary incontinence who have failed oral pharmacologic therapy. This study will test the broad hypothesis that administration of Botox/DMSO instillations into the bladder with a urethral catheter can significantly improve symptoms and quality of life in patients with OAB when compared to DMSO installations alone. Explicitly, we hypothesize that scores on the validated Incontinence Quality of Life (I-QOL) questionnaire of women with OAB who receive Botox/DMSO instillation will be much improved at three-month follow-up compared to similar women receiving DMSO instillation alone. Our long-term goal is to offer women with detrusor hyperreflexia or OAB a less invasive alternative to surgery and an alternative to anticholinergic by mouth medications. In support of this effort, we are proposing a randomized, double-blind, placebo controlled clinical trial to be conducted in the Department of Urology at Mayo Clinic, Jacksonville, Florida.

Note: The study was terminated early in July of 2011 due to an extended medical absence of the Principal Investigator.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 25
• Est. completion date: January 2012
• Est. primary completion date: January 2012
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Female patient aged 18 years or older

• No evidence of stress urinary incontinence on physical examination or urodynamics

• Patients who have failed prior drug therapy for overactive bladder or detrusor hyperreflexia

• Patients with symptoms and signs of OAB, detrusor hyperreflexia, urinary urgency, urinary urge incontinence.

• Patient who is mentally competent with the ability to understand and comply with the requirements of the study

• Patient who agrees to be available for the follow-up evaluations as required by the protocol

• Patient who has given signed informed consent

Exclusion Criteria:

• Patient with Post-Void Residual Urine (PVRU) greater than 100 ml on repeated measures. (Patient with a single PVRU of >100 ml and followed by two consecutive PVRU measurements of <100 ml may be included in the study)

• Patient with greater than vesicoureteral reflux grade 1, interstitial cystitis, genitourinary fistulae

• Patient with pelvic organ prolapse stage III or IV, i.e. the most distal part of the prolapse protruding more than 1 cm beyond the hymen (>+1), at straining

• Patient with un-investigated hematuria

• Patient with lower tract genitourinary malignancies

• Patient on current medication for stress urinary incontinence, such as alpha-adrenergic agonists or duloxetine, within three weeks prior to completing the baseline Bladder Diary (estrogen therapy on a stable dose for at least two months prior to study start is allowed)

• Patient with ongoing complications of prior anti-incontinence surgery

• Patient who is pregnant, lactating, or planning to become pregnant within the study period

• Patient who has received pelvic radiation

• Patient with any condition, which could lead to significant postoperative complications, including current infection and uncontrolled diabetes.

• Patient who is morbidly obese (defined as BMI > 40 Kg/m2)

• Patient who is bedridden, institutionalized or in such physical condition that she cannot move to the closest bathroom without assistance from another person

• Patient with current or acute urinary tract infection, including cystitis or urethritis. (Patient with such infections should be treated with antibiotics, with subsequent urinalysis tests confirming the absence of such infection before study inclusion)

• Patient with any condition that would preclude treatment due to contraindications and/or warnings in the study product's labeling

• Patient on immunomodulatory therapy (suppressive or stimulatory)

• Patient with known lidocaine hypersensitivity or hypersensitivity to any anesthetics to be used during the treatment session/surgical procedure

• Patient with a concurrent use of another study product within two weeks prior to study start, or who concurrently participate in any other clinical study

• Any disease that in the opinion of the Investigator would make the patient unsuitable for the study

• Patient with a life expectancy of less than 12 months

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Detrusor Hyperreflexia
• Overactive Bladder
• Urge Incontinence
• Urinary Bladder, Overactive
• Urinary Incontinence
• Urinary Incontinence, Urge
• Urinary Urge Incontinence

Intervention

Drug:
• Botox Instillation
Botox instilled into the bladder via ureteral catheter and retained for up to 30 minutes then spontaneously voided.
• DMSO Instillation
DMSO 50% w/w aqueous solution; 50 cubic centimeters instilled into the bladder via ureteral catheter and retained up to 30 minutes then spontaneously voided.

Locations

Country	Name	City	State
United States	Mayo Clinic	Jacksonville	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

References & Publications (1)

Petrou SP, Parker AS, Crook JE, Rogers A, Metz-Kudashick D, Thiel DD. Botulinum a toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: a phase 1/2 study. Mayo Clin Proc. 2009 Aug;84(8):702-6. doi: 10.1016/S0025-6196(11)60520-X. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Incontinence Quality of Life (I-QoL) Score	The I-QoL measures the effect of urinary incontinence on quality of life. It is divided into 3 subscales: 1) avoidance and limiting behavior, 2) psychosocial impact, and 3) social embarrassment. The I-QOL is comprised of 22 items, each with the response scale from '1= Extremely' to '5= Not at all'.; A mean score for each subscale is calculated (averaging the scores for the items in each subscale) as well as a total score for all 22 items (sum of all subscale scores). The scores are then transformed to a 'Scale score' ranging from 0-100 points for ease of interpretation: Scale score = (sum of the items - lowest possible score)/possible raw score range X 100. Higher scores indicate less impact of incontinence on quality of life.	Baseline, 1 month, 3 months	No
Secondary	Change in Incontinence Impact Questionnaire Short Form (IIQ-7)	The IIQ-7 measures the effect of urinary incontinence on quality of life. It is comprised of 7 items, each with the response scale from "0=Not at all" to "3=Greatly." The scores can range from 0 to 21; a low score indicates less impact of incontinence on quality of life.	baseline, 1 month, 3 months	No
Secondary	Change in International Consultation on Incontinence Questionnaire - Short Form Score (ICIQ-SF)	The ICIQ-SF provides a brief and robust measure to assess the impact of symptoms of incontinence on quality of life and outcome of treatment. The questionnaire has 4 items and the score can range from 0 to 21, with greater values indicating increased severity of symptoms and lower quality of life.	baseline, 1 month, 3 months	No
Secondary	Change in Urogenital Distress Inventory (UDI-6)	The UDI-6 measures the effect of urinary incontinence on quality of life. It consists of 6 items, each with the response scale from "0=Not at all" to "3=Greatly." The scores can range from 0 to 18; a low score indicates less impact of incontinence on quality of life.	baseline, 1 month, 3 months	No
Secondary	Number of Participants With Decrease in Blaivas-Groutz Anti-Incontinence Score at 1 Month and 3 Months	The Blaivas-Groutz Anti-incontinence scale was used as a measure of urinary incontinence. This scale combines information on the number of incontinent episodes in a 24-hour period, 24-hour pad weights, and a qualitative rating by the patient into a single score ranging from 0 to 6. this score is then used to categorize incontinence as none (0), mild (1-2), moderate (3-4), or severe (5-6).	baseline, 1 month, 3 months	No
Secondary	Number of Participants With a Decrease in Urinary Urgency at 1 Month and 3 Months	Urinary urgency was measured by the Indevus Urgency Severity Scale (IUSS). The IUSS asks patients to assess the severity of 'urgency' at each void. The scale employs the following wording: "Degree of urgency is meant to describe your urge to urinate. Sometimes you may feel a very strong urge to urinate and at other times, you may feel a milder urge prior to the onset of a toilet void. Rate this feeling by circling 0, 1, 2, or 3, defined as: 0: NONE - no urgency, 1: MILD - awareness of urgency, but it is easily tolerated and you can continue with your usual activity or tasks, 2: MODERATE - enough urgency discomfort that it interferes with or shortens your usual activity or tasks, 3: SEVERE - extreme urgency discomfort that abruptly stops all activity or tasks."	Baseline, 1 month, 3 months	No

External Links

•   Mayo Clinic Clinical Trials